Exploration of platinum-induced neuropathy should be based on both objective and subjective examinations

References

• Fossa SD. Long-term sequelae after cancer therapy – Survivorship after treatment for testicular cancer. Acta Oncol 2004; 43: 134–141
   PubMed Web of Science ®Google Scholar
• Nord C, Ganz PA, Aziz N, Fossa SD. Follow-up of long-term cancer survivors in the Nordic countries. Acta Oncol 2007; 46: 433–440
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper J, Ahnen D, Hamilton S, et al. Priorities in colorectal cancer research: Recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. J Clin Oncol 2007; 25: 2313–2321
   PubMedGoogle Scholar
• Brouwers, E, Huitema, A, Boogerd, W, Beijnen, J, Schellens, J. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009, (in press).
   PubMedGoogle Scholar
• Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006; 33: 15–49
   PubMed Web of Science ®Google Scholar
• Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005; 146: 1027–1039
   PubMed Web of Science ®Google Scholar
• Meijer C, de Vries EGE, Marmiroli P, Tredici G, Frattola L, Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999; 20: 883–887
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001; 85: 1219–1225
   PubMed Web of Science ®Google Scholar
• McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity 195. Neurobiol Dis 2005; 18: 305–313
   PubMed Web of Science ®Google Scholar
• Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile(105)Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 3050–3056
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25: 708–714
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007; 5: 70
   PubMed Web of Science ®Google Scholar
• Shukla SJ, Duan S, Badner JA, Wu XL, Dolan ME. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 2008; 18: 253–262
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003; 61: 1297–1300
   PubMed Web of Science ®Google Scholar
• Jensen K. Measuring side effects after radiotherapy for pharynx cancer. Acta Oncol 2007; 46: 1051–1063
   PubMed Web of Science ®Google Scholar
• Ebenezer GJ, Hauer P, Gibbons C, McArthur JC, Polydefkis M. Assessment of epidermal nerve fibers: A new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol 2007; 66: 1059–1073
   PubMed Web of Science ®Google Scholar
• Gibbons CH, Illigens BM, Centi J, Freeman R. QDIRT: Quantitative direct and indirect test of sudomotor function. Neurology 2008; 70: 2299–2304
   PubMedGoogle Scholar
• Grov, EK, Dahl, AA, Fossa, SD. Neuroticism. Acta Oncol 2009, (in press).
   PubMedGoogle Scholar
• Knap MM, Bentzen SM, Overgaard J. Late neurological complications after irradiation of malignant tumors of the testis. Acta Oncol 2007; 46: 497–503
   PubMed Web of Science ®Google Scholar
• Brydoy M, Storstein A, Dahl O. Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma. Radiother Oncol 2007; 82: 137–144
   PubMedGoogle Scholar
• Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical 2008 Oncology clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27: 127–145
   PubMed Web of Science ®Google Scholar
• Kaley, TJ, Deangelis, LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009.
   PubMedGoogle Scholar